You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKesson
McKinsey
Harvard Business School
Moodys
AstraZeneca
Mallinckrodt

Last Updated: February 26, 2020

DrugPatentWatch Database Preview

Patent: 7,728,010

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,728,010
Title:Substituted benz-azoles and methods of their use as inhibitors of Raf kinase
Abstract: New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.
Inventor(s): Amiri; Payman (Walnut Creek, CA), Fantl; Wendy (San Francisco, CA), Hansen; Teresa (Danville, CA), Levine; Barry Haskell (Lafayette, CA), McBride; Christopher (Oakland, CA), Poon; Daniel J (Oakland, CA), Ramurthy; Savithri (Walnut Creek, CA), Renhowe; Paul A (Danville, CA), Shafer; Cynthia M (El Sobrante, CA), Subramanian; Sharadha (San Ramon, CA), Sung; Leonard (Irvine, CA)
Assignee: Novartis Vaccines and Diagnostics, Inc. (Emeryville, CA)
Application Number:11/282,939
Patent Claims:see list of patent claims

Details for Patent 7,728,010

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial Novartis Vaccines and Diagnostics, Inc. (Emeryville, CA) 2022-03-29 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial Novartis Vaccines and Diagnostics, Inc. (Emeryville, CA) 2022-03-29 RX search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial Novartis Vaccines and Diagnostics, Inc. (Emeryville, CA) 2022-03-29 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial Novartis Vaccines and Diagnostics, Inc. (Emeryville, CA) 2022-03-29 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial Novartis Vaccines and Diagnostics, Inc. (Emeryville, CA) 2022-03-29 RX Orphan search
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28   Start Trial Novartis Vaccines and Diagnostics, Inc. (Emeryville, CA) 2022-03-29 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Boehringer Ingelheim
McKesson
Colorcon
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.